Nanoengineered T cell system for the in vitro treatment of oral squamous cell carcinoma

doi:10.3969/j.issn.1674-8115.2025.07.008

Abstract

Abstract:

Objective ·To construct a nanoengineered T cell system and explore its synergistic efficacy in the in vitro treatment of oral squamous cell carcinoma, and provide a new strategy for this disease. Methods ·Zr-MOF nanoparticles with a highly hydrophilic hyaluronic acid (HA) coating (PCN224-HA NPs) were prepared, and their carboxyl groups were activated to enable coupling with anti-CD45 antibodies through an amide reaction. High-purity CD8⁺ T cells were then extracted from the spleens of mice, and the PCN224-HA NPs were loaded onto the T cells via the CD45 antigens on their surface. The coupling was observed using bioelectron microscopy and confocal microscopy, and free radical generation was detected under ultrasound irradiation. The viability of Cal27 cells was recorded by a microplate reader to explore therapeutic effects in vitro. Results ·PCN224-HA NPs were successfully synthesized and confirmed to be coupled onto the surface of CD8⁺ T cells, constructing a nanoengineered T cell system (T cells@PCN224-HA NPs). Free radical production was monitored after ultrasound irradiation and the viability of Cal27 cells decreased to 31.70% after in vitro treatment. Conclusions ·Preliminary experiments demonstrated that the nanoparticles can be successfully loaded onto the surface of T cells, providing combined sonodynamic therapeutic effects from the nanoparticles and immunocidal effects from the T cells. This offers a novel strategy for the treatment of oral squamous cell carcinoma, with potential for further in vivo anti-tumor experiments and therapeutic applications.

Key words: oral squamous cell carcinoma, sonodynamic therapy, immunotherapy, nanoengineered T cells, PCN224-HA nanoparticle, CD8⁺ T cell, synergistic therapy

CLC Number:

R730.5

MENG Jing, XIE Yuting, ZUO Jiaxin, XIONG Ping. Nanoengineered T cell system for the in vitro treatment of oral squamous cell carcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 866-873.

Figures/Tables 5

Fig 1 Schematic representation of the synthesis of the T cell @PCN224-HA system with sonodynamic activity

Fig 2 Structural characterization of PCN224 and PCN224-HA nanoparticles

Fig 3 Observation of PCN224-HA nanoparticles coupled to the surface of T cells

Fig 4 Sonodynamic performance of PCN224-HA and PH T cells

Fig 5 In vitro therapeutic experiments of PH T cells against Cal27 cells

TrendMD

References 31

[1]	JOHNSON D E, BURTNESS B, LEEMANS C R, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92.
[2]	CHOW L Q M. Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72.
[3]	TABERNA M, MENA M, PAVÓN M A, et al. Human papillomavirus-related oropharyngeal cancer[J]. Ann Oncol, 2017, 28(10): 2386-2398.
[4]	GRABOYES E M, KOMPELLI A R, NESKEY D M, et al. Association of treatment delays with survival for patients with head and neck cancer: a systematic review[J]. JAMA Otolaryngol Head Neck Surg, 2019, 145(2): 166-177.
[5]	SOLOMON B, YOUNG R J, RISCHIN D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments[J]. Semin Cancer Biol, 2018, 52(Pt 2): 228-240.
[6]	HANNA G J, O'NEILL A, SHIN K Y, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2022, 28(3): 468-478.
[7]	MACHIELS J P, RENÉ LEEMANS C, GOLUSINSKI W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(11): 1462-1475.
[8]	CRAMER J D, BURTNESS B, LE Q T, et al. The changing therapeutic landscape of head and neck cancer[J]. Nat Rev Clin Oncol, 2019, 16(11): 669-683.
[9]	TANG Z M, ZHAO P R, WANG H, et al. Biomedicine meets Fenton chemistry[J]. Chem Rev, 2021, 121(4): 1981-2019.
[10]	LIN X H, SONG J B, CHEN X Y, et al. Ultrasound-activated sensitizers and applications[J]. Angew Chem Int Ed, 2020, 59(34): 14212-14233.
[11]	XU M M, ZHOU L Q, ZHENG L, et al. Sonodynamic therapy-derived multimodal synergistic cancer therapy[J]. Cancer Lett, 2021, 497: 229-242.
[12]	ZHANG Y, ZHANG C F, QIAN W L, et al. Recent advances in MOF-based nanozymes: synthesis, activities, and bioapplications[J]. Biosens Bioelectron, 2024, 263: 116593.
[13]	HU Y H, ZHENG Y J, LIU C, et al. Mitochondrial MOF regulates energy metabolism in heart failure via ATP5B hyperacetylation[J]. Cell Rep, 2024, 43(10): 114839.
[14]	MALEKI A, SEYEDHAMZEH M, YUAN M, et al. Titanium-based nanoarchitectures for sonodynamic therapy-involved multimodal treatments[J]. Small, 2023, 19(12): e2206253.
[15]	XIE X X, ZHANG J X, WANG Y, et al. Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy[J]. Mater Today Bio, 2023, 24: 100926.
[16]	ZHANG N S, ZENG W L, XU Y X, et al. Pyroptosis induction with nanosonosensitizer-augmented sonodynamic therapy combined with PD-L1 blockade boosts efficacy against liver cancer[J]. Adv Healthc Mater, 2024, 13(7): e2302606.
[17]	JIANG H, YANG K W, ZHAO X X, et al. Highly stable Zr(IV)-based metal-organic frameworks for chiral separation in reversed-phase liquid chromatography[J]. J Am Chem Soc, 2021, 143(1): 390-398.
[18]	PARK J, JIANG Q, FENG D W, et al. Size-controlled synthesis of porphyrinic metal-organic framework and functionalization for targeted photodynamic therapy[J]. J Am Chem Soc, 2016, 138(10): 3518-3525.
[19]	LÁZARO I A, WELLS C J R, FORGAN R S. Multivariate modulation of the Zr MOF UiO-66 for defect-controlled combination anticancer drug delivery[J]. Angew Chem Int Ed, 2020, 59(13): 5211-5217.
[20]	HAO F, YAN Z Y, YAN X P. Intracellular fate and immune response of porphyrin-based nano-sized metal-organic frameworks[J]. Chemosphere, 2022, 307: 135680.
[21]	SNETKOV P, ZAKHAROVA K, MOROZKINA S, et al. Hyaluronic acid: the influence of molecular weight on structural, physical, physico-chemical, and degradable properties of biopolymer[J]. Polymers (Basel), 2020, 12(8): 1800.
[22]	GHOSH B, BISWAS S. Polymeric micelles in cancer therapy: state of the art[J]. J Control Release, 2021, 332: 127-147.
[23]	KYU SHIM M, YANG S, SUN I C, et al. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: preclinical evidence for safe and effective drug delivery[J]. Adv Drug Deliv Rev, 2022, 183: 114177.
[24]	LIU Y T, SUN Z J. Turning cold tumors into hot tumors by improving T-cell infiltration[J]. Theranostics, 2021, 11(11): 5365-5386.
[25]	LIU C P, WANG Y C, LI L M, et al. Engineered extracellular vesicles and their mimetics for cancer immunotherapy[J]. J Control Release, 2022, 349: 679-698.
[26]	HIAM-GALVEZ K J, ALLEN B M, SPITZER M H. Systemic immunity in cancer[J]. Nat Rev Cancer, 2021, 21(6): 345-359.
[27]	HUANG Z C, LIU L P, ZHU Z Y, et al. Tuning surface valences of nanoengagers to enhance their structural advantages for efficiently redirecting T cells against solid tumors[J]. ACS Nano, 2025, 19(1): 381-395.
[28]	MIN H, WANG J, QI Y Q, et al. Biomimetic metal-organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy[J]. Adv Mater, 2019, 31(15): e1808200.
[29]	WANG Y F, SHI J Q, XIN M H, et al. Cell-drug conjugates[J]. Nat Biomed Eng, 2024, 8(11): 1347-1365.
[30]	GAO H B, SUN L, WANG H, et al. In situ non-canonical activation and sensitization of cGAS-STING pathway with manganese telluride nanosheets[J]. Biomaterials, 2025, 318: 123170.
[31]	SUN Z H, LIU J, LI Y Y, et al. Aggregation-induced-emission photosensitizer-loaded nano-superartificial dendritic cells with directly presenting tumor antigens and reversed immunosuppression for photodynamically boosted immunotherapy[J]. Adv Mater, 2023, 35(3): e2208555.